{"cluster": 63, "subcluster": 3, "abstract_summ": "Recognizing the need for robust randomized control trials, the World Health Organization (WHO) recently organized a multinational randomized trial-the SOLIDARITY trial-to study the effect of drugs that have been identified as promising based on in-vitro data and the early clinical experience with COVID-19: Remdesivir, lopinavir and ritonavir; lopinavir and ritonavir + interferon; and chloroquine or hydroxychloroquine.It has been reported that hydroxychloroquine (HCQ) is active against SARS-CoV-2 in vitro, and this finding was quickly supported by an open label non-randomized clinical trial that provided the first published clinical evidence HCQ may be a treatment option.Here, we advocate for randomized double-blind placebo controlled clinical trials to evaluate promising agents early during SARS Co-V-2 infection.Here we review evidence of the 8 most recent reports including 3 randomized controlled trials on the clinical efficacy of remdesivir in treating COVID-19 patient.In this review, we analyze pertinent clinical remdesivir data for patients with COVID-19 from January 1, 2020, through May 31, 2020.The global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS\u2010Co\u2010V\u20102) has resulted in a critical need to rapidly develop new pharmacologic interventions and disseminate information.", "title_summ": "What do we have and where are we going?COVID-19: An Update about the Discovery Clinical TrialResponse to: Optimizing Hydroxychloroquine Dosing for Patients With COVID\u201019: An Integrative Modeling Approach for Effective Drug Repurposing: Quantitative Clinical Pharmacology Input to SARS\u2010CoV\u20102 Therapeutics Should Be Based on Robust DataHydroxychloroquine for Treatment of SARS\u2010CoV\u20102 Infection?An opinion pieceThat Escalated Quickly: Remdesivir's Place in Therapy for COVID-19What do we know about remdesivir drug interactions?Remdesivir investigational trials in COVID-19: a critical reappraisalOff\u2010Label Therapies for COVID\u201019\u2014Are We All In This Together?A Real\u2010World Evidence Framework for Optimising Dosing in All Patients with COVID\u201019Improving Our Confidence in a Model\u2010Based Approach to Dose SelectionCOVID\u201019: A review of therapeutics under investigationAntiretroviral HIV drugs in COVID\u201019 research: promises and risks.An early test and treat strategy for SARS-CoV-2Treatment and research lines for the patient with COVID-19.", "title_abstract_phrases": "Here, we advocate for randomized double-blind placebo controlled clinical trials to evaluate promising agents early during SARS Co-V-2 infection.Recognizing the need for robust randomized control trials, the World Health Organization (WHO) recently organized a multinational randomized trial-the SOLIDARITY trial-to study the effect of drugs that have been identified as promising based on in-vitro data and the early clinical experience with COVID-19: Remdesivir, lopinavir and ritonavir; lopinavir and ritonavir + interferon; and chloroquine or hydroxychloroquine.Response to: Optimizing Hydroxychloroquine Dosing for Patients With COVID\u201019: An Integrative Modeling Approach for Effective Drug Repurposing: Quantitative Clinical Pharmacology Input to SARS\u2010CoV\u20102 Therapeutics Should Be Based on Robust DataWith impressive speed Garcia-Cremades et al[1] have modelled the association between hydroxychloroquine (HCQ) and viral load, merging literature in vitro data and data from a recently published clinical study (which as of April 11 2020 is under investigation by the publisher[2]).It has been reported that hydroxychloroquine (HCQ) is active against SARS-CoV-2 in vitro, and this finding was quickly supported by an open label non-randomized clinical trial that provided the first published clinical evidence HCQ may be a treatment option.In this review, we analyze pertinent clinical remdesivir data for patients with COVID-19 from January 1, 2020, through May 31, 2020.What do we know about remdesivir drug interactions?The global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS\u2010Co\u2010V\u20102) has resulted in a critical need to rapidly develop new pharmacologic interventions and disseminate information."}